HomeCompareOSMT vs GIS

OSMT vs GIS: Dividend Comparison 2026

OSMT yields 180.18% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OSMT wins by $66.03M in total portfolio value
10 years
OSMT
OSMT
● Live price
180.18%
Share price
$1.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$66.11M
Annual income
$31,604,469.02
Full OSMT calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — OSMT vs GIS

📍 OSMT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOSMTGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OSMT + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OSMT pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OSMT
Annual income on $10K today (after 15% tax)
$15,315.32/yr
After 10yr DRIP, annual income (after tax)
$26,863,798.67/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, OSMT beats the other by $26,849,933.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OSMT + GIS for your $10,000?

OSMT: 50%GIS: 50%
100% GIS50/50100% OSMT
Portfolio after 10yr
$33.09M
Annual income
$15,810,390.22/yr
Blended yield
47.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on OSMT right now

OSMT
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-8.0
Piotroski
3/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OSMT buys
0
GIS buys
0
No recent congressional trades found for OSMT or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOSMTGIS
Forward yield180.18%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$66.11M$79.2K
Annual income after 10y$31,604,469.02$16,311.42
Total dividends collected$61.93M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: OSMT vs GIS ($10,000, DRIP)

YearOSMT PortfolioOSMT Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$28,718$18,018.02$11,504$804.11+$17.2KOSMT
2$79,087$48,359.04$13,371$1,061.65+$65.7KOSMT
3$209,088$124,464.74$15,723$1,416.15+$193.4KOSMT
4$531,253$307,528.35$18,735$1,911.16+$512.5KOSMT
5$1,298,693$730,252.50$22,660$2,613.51+$1.28MOSMT
6$3,057,980$1,668,378.52$27,874$3,627.81+$3.03MOSMT
7$6,943,500$3,671,461.50$34,947$5,121.52+$6.91MOSMT
8$15,220,649$7,791,104.22$44,762$7,369.21+$15.18MOSMT
9$32,247,458$15,961,362.93$58,728$10,832.80+$32.19MOSMT
10$66,109,249$31,604,469.02$79,151$16,311.42+$66.03MOSMT

OSMT vs GIS: Complete Analysis 2026

OSMTStock

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Full OSMT Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this OSMT vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OSMT vs SCHDOSMT vs JEPIOSMT vs OOSMT vs KOOSMT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.